Green Car Congress  
Go to GCC Discussions forum About GCC Contact  RSS Subscribe Twitter headlines

« Cummins announces fuel economy improvements for heavy-duty lineup | Main | BMW to invest $1B in Spartanburg, SC plant by 2016 to increase capacity by 50%; new BMW X7 »

Print this post

Synthetic biology company launches JV to commercialize gas-to-liquids bioconversion; isobutanol first target

28 March 2014

Synthetic biology company Intrexon Corporation has formed Intrexon Energy Partners (IEP), a joint venture with a group of external investors, to optimize and to scale-up Intrexon’s gas-to-liquids (GTL) bioconversion platform. IEP’s first target product is isobutanol for gasoline blending.

Intrexon’s natural gas upgrading program is targeting the development of an engineered microbial cell line for industrial-scale bioconversion of natural gas to chemicals, lubricants and fuels, as opposed to employing standard chemical routes. Intrexon says it has already achieved initial proof of concept with an engineered microbial host converting methane into isobutanol in a laboratory-scale bioreactor.

Intrexon says that its biocatalyst approach to GTL bioconversion reduces energy use, production costs, and waste while producing a single high value product. It thus offers economic advantages over traditional conversion platforms that rely on costly thermochemical catalytic processes, such as the Fischer-Tropsch method of carbon upgrading, or depend on available plant-based feedstocks. IEP will utilize natural gas as its feedstock—a less expensive carbon source than biomass or sugar-based technologies.

Methanotrophic bacteria oxidize methane as their sole carbon source to support cellular metabolism and growth. However, notes Intrexon, a lack of requisite tools and detailed microbial regulatory and physiological information make methanotrophs challenging to engineer genetically.

Intrexon developed a suite of tools enabling the rapid manipulation of methanotrophic organisms including gene knock in/out, direct transformation/electroporation, and plasmid-based expression systems.

Although Intrexon’s engineered methanotroph produces isobutanol, commercial scale-up is a challenge; expression of a heterologous pathway for product generation places additional metabolic burdens on the cell, as carbon is diverted from primary to exogenous metabolic pathways for product production.

Intrexon says that it has developed a fermentation bioreactor protocol that supports growth of an isobutanol producing engineered methanotroph at industrially relevant cell densities. In addition, the company is developing a high-throughput platform to test and iteratively to optimize media composition and strain performance while also facilitating rapid design and testing of new pathways for improved isobutanol production from engineered strains.

(Dr. Eli Groban, Intrexon’s Director of Metabolic Engineering and Systems Biology in the Industrial Products Division and leader of the methane bioconversion program is presenting on the company’s natural gas bioconversion platform at Bio’s upcoming World Congress on Industrial Biotechnology in Philadelphia in May. Prior to Intrexon, Groban was at LS9.)

Through an Exclusive Channel Collaboration (ECC) agreement, IEP will pay Intrexon a $25-million technology access fee to leverage the company’s synthetic biology capabilities, including the UltraVector platform, to further enhance the performance of a target biocatalyst.

In addition, IEP, in which Intrexon owns a 50% interest, will invest up to $50 million dollars in program development costs. Simultaneously, Intrexon entered into securities purchase agreements with the external investors in IEP for the private placement of 972,004 shares of common stock at a price of $25.72 per share for gross proceeds of $25 million.

March 28, 2014 in Biobutanol, Biotech, Gas-to-Liquids (GTL), Natural Gas, Synthetic Biology | Permalink | Comments (5) | TrackBack (0)

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341c4fbe53ef01a3fce195dc970b

Listed below are links to weblogs that reference Synthetic biology company launches JV to commercialize gas-to-liquids bioconversion; isobutanol first target:

Comments

ICI made Pruteen, protein cattle food, from methane using an organism found on an athletic field, and invented large scale equipment to do it. Converting the methane to hydrogen and CO could allow the production of ethanol directly with known organisms. The methane can be from anaerobic digestion. Converting methane to liquid fuels could be the most important project of the century. It is not hard to make liquid methane and to keep it cold ith modern equipment on the other hand. ..HG..

There are lot of locations worldwide where due to low quantities of natural gas or biogas it does not makes sense to liquidize or connect to natural gas delivery network. In such cases this could be perfect solution such GTL solutions.

Consider Japan, no natural gas, no oil and no coal. However they DO have lots of food waste that can go into digester systems to make methane. Convert the methane into bio fuels to put in hybrid cars.

Every time I fart, i think about them.. gor

gor,

That kind of comment we don't need. Keep it up and I will email the site.

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been posted. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Green Car Congress © 2013 BioAge Group, LLC. All Rights Reserved. | Home | BioAge Group